"We have started all our modern Redio therapy, PET, CT and Nuclear Medicine division with affordable cost in our hospital at Nayabad, Garia. Open 24 X 7."

During the past decade, Netaji Subhash Chandra Bose Cancer Research Institute conducted 6 clinical trials. In the 10-year time frame, 6 clinical trials started and 4 clinical trials were completed, i.e. on average, 66.7% percent of trials that started reached the finish line to date. In the past 5 years, 4 clinical trials started and 3 clinical trials were completed. i.e. 75% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Netaji Subhash Chandra Bose Cancer Research Institute" #1 sponsor was "Pfizer" with 2 trials, followed by "mAbxience Research S.L." with 2 trials sponsored, "Amgen" with 1 trials sponsored, "Christian Medical College, Vellore, India" with 1 trials sponsored and "Grifols Biologicals, LLC" with 1 trials sponsored. Other sponsors include -2 different institutions and companies that sponsored additional 8 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Netaji Subhash Chandra Bose Cancer Research Institute" #1 collaborator was "Actoverco" with 1 trials as a collaborator, "Astellas Pharma Inc" with 1 trials as a collaborator, "Innogene Kalbiotech Pte. Ltd" with 1 trials as a collaborator, "Instituto Grifols, S.A." with 1 trials as a collaborator and "Key Oncologics (Pty) Ltd" with 1 trials as a collaborator. Other collaborators include 2 different institutions and companies that were collaborators in the rest 12 trials.

According to Clinical.Site data, the most researched conditions in "Netaji Subhash Chandra Bose Cancer Research Institute" are "Acute Promyelocytic Leukemia" (1 trials), "Diffuse Large B-cell Lymphoma" (1 trials), "Idiopathic Thrombocytopenic Purpura" (1 trials), "Metastatic Castrate Sensitive Prostate Cancer" (1 trials) and "Metastatic Non Small Cell Lung Cancer" (1 trials). Many other conditions were trialed in "Netaji Subhash Chandra Bose Cancer Research Institute" in a lesser frequency.

Most popular intervention types in "Netaji Subhash Chandra Bose Cancer Research Institute" are "Drug" (8 trials) and "Biological" (2 trials). Other intervention types were less common.

The name of intervention was led by "Abiraterone acetate (AA)" (1 trials), "Bortezomib" (1 trials), "Carboplatin" (1 trials), "Dacomitinib" (1 trials) and "Dexamethasone" (1 trials). Other intervention names were less common.

The vast majority of trials in "Netaji Subhash Chandra Bose Cancer Research Institute" are 8 trials for "All" genders and 2 trials for "Male" genders.

Currently, there are NaN active trials in "Netaji Subhash Chandra Bose Cancer Research Institute". undefined are not yet recruiting, 1 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 5 completed trials in Netaji Subhash Chandra Bose Cancer Research Institute, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Netaji Subhash Chandra Bose Cancer Research Institute, 1 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 7 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 0 trials that are defined as “Not Applicable".